Latest Stock Market News

The Gurgaon-based company witnessed a decline in its volume, which coupled with hardening raw material inflation, negated the impact of improvement in price realisations and dented the performance of the company in October-December, reports said.

The company’s EBITDA (earnings before interest, tax, depreciation and amortization) dipped 21.3 per cent to Rs 109 crore in Q3 FY22 over Rs 139 crore in Q3 FY21. The EBITDA margin stood at 22 per cent in the third quarter of the current financial year as compared to 30.7 per cent a year ago.

A faster-than-envisaged pace of rate hikes in the US could exacerbate a recent spree of selling pressure displayed by foreign investors in Indian equities, especially as the Reserve Bank of India has refrained from normalizing ultra-loose pandemic-era monetary policy, dealers said.

A total of 19,173 shares changed hands on the counter till 11:32AM (IST)

The stock traded at a P/E multiple of 37.47, while the price-to-book value ratio stood at 12.79.

"US inflation in January came worse-than-expected at 7.5 per cent pushing the 10-year yield to 2.03 per cent discounting a hawkish Fed, which may raise rates by at least by 100 basis points this year. A rate hike by even 50 bps in March is looking increasingly probable now. This is not good news for global equity markets," V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services, said.

According to the data from National Stock Exchange (NSE), about 77.98 lakh shares of PB Fintech changed hands, whereas 5.82 lakh shares were traded on BSE

Dr. Lal Pathlabs Ltd., incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 23488.67 Crore) operating in Hospitals & Allied Services sector.

Promoters held 50.48 per cent stake in the company as of 31-Dec-2021, while FII and DII ownership stood at 13.02 per cent and 3.13 per cent, respectively.

The stock traded at a P/E multiple of 52.37, while the price-to-book value ratio stood at 8.04.